Baseline cohort characteristics (N = 448)
| . | % (n) . |
|---|---|
| Age (n = 448), y | |
| 75-79 | 55.8 (250) |
| 80-84 | 31.0 (139) |
| 84+ years | 13.2 (59) |
| Sex (n = 448) | |
| Female | 34.8 (156) |
| Male | 65.2 (292) |
| Treatment type (n = 415) | |
| Nonintensive* | 45.3 (188) |
| Intensive | 54.7 (227) |
| Cancer aggressiveness (n = 448) | |
| Aggressive† | 62.5 (280) |
| Indolent‡ | 37.5 (168) |
| Cancer type (n = 448) | |
| Myeloid neoplasms§ | 17.6 (79) |
| Plasma cell neoplasms¶ | 30.6 (137) |
| NHLs|| | 28.6 (128) |
| Other | 23.2 (104) |
| CCI#(n = 448) | |
| <3 | 36.2 (162) |
| 3-4 | 40.0 (179) |
| 5+ | 23.9 (107) |
| 5-word delayed recall (n = 448) | |
| Probable impairment (≥2 errors) | 18.3 (82) |
| Normal (0 or 1 error) | 81.7 (366) |
| Executive function (n = 448) | |
| Probable impairment (CIB score < 5) | 22.5 (101) |
| Normal (CIB score = 5-8) | 77.5 (347) |
| ECOG PS (n = 272) | |
| 0 | 44.1 (120) |
| 1 | 38.6 (105) |
| 2 | 12.9 (35) |
| 3 | 4.4 (12) |
| Gait speed, m/s (n = 448) | |
| <0.40 | 7.8 (35) |
| 0.40-0.60 | 13.2 (59) |
| 0.60-0.80 | 35.0 (157) |
| ≥0.80 | 44.0 (197) |
| Grip strength, kg (n = 448) | |
| <20 | 38.6 (173) |
| 20-30 | 33.3 (149) |
| >30 | 28.1 (126) |
| Phenotype frailty index (n = 448) | |
| Robust (0) | 31.0 (139) |
| Prefrail (1-2) | 57.2 (256) |
| Frail (3+) | 11.8 (53) |
| Cumulative deficit index (n = 448) | |
| Robust (0-0.2) | 49.1 (220) |
| Prefrail (0.2-0.35) | 35.3 (158) |
| Frail (0.35-1) | 15.6 (70) |
| . | % (n) . |
|---|---|
| Age (n = 448), y | |
| 75-79 | 55.8 (250) |
| 80-84 | 31.0 (139) |
| 84+ years | 13.2 (59) |
| Sex (n = 448) | |
| Female | 34.8 (156) |
| Male | 65.2 (292) |
| Treatment type (n = 415) | |
| Nonintensive* | 45.3 (188) |
| Intensive | 54.7 (227) |
| Cancer aggressiveness (n = 448) | |
| Aggressive† | 62.5 (280) |
| Indolent‡ | 37.5 (168) |
| Cancer type (n = 448) | |
| Myeloid neoplasms§ | 17.6 (79) |
| Plasma cell neoplasms¶ | 30.6 (137) |
| NHLs|| | 28.6 (128) |
| Other | 23.2 (104) |
| CCI#(n = 448) | |
| <3 | 36.2 (162) |
| 3-4 | 40.0 (179) |
| 5+ | 23.9 (107) |
| 5-word delayed recall (n = 448) | |
| Probable impairment (≥2 errors) | 18.3 (82) |
| Normal (0 or 1 error) | 81.7 (366) |
| Executive function (n = 448) | |
| Probable impairment (CIB score < 5) | 22.5 (101) |
| Normal (CIB score = 5-8) | 77.5 (347) |
| ECOG PS (n = 272) | |
| 0 | 44.1 (120) |
| 1 | 38.6 (105) |
| 2 | 12.9 (35) |
| 3 | 4.4 (12) |
| Gait speed, m/s (n = 448) | |
| <0.40 | 7.8 (35) |
| 0.40-0.60 | 13.2 (59) |
| 0.60-0.80 | 35.0 (157) |
| ≥0.80 | 44.0 (197) |
| Grip strength, kg (n = 448) | |
| <20 | 38.6 (173) |
| 20-30 | 33.3 (149) |
| >30 | 28.1 (126) |
| Phenotype frailty index (n = 448) | |
| Robust (0) | 31.0 (139) |
| Prefrail (1-2) | 57.2 (256) |
| Frail (3+) | 11.8 (53) |
| Cumulative deficit index (n = 448) | |
| Robust (0-0.2) | 49.1 (220) |
| Prefrail (0.2-0.35) | 35.3 (158) |
| Frail (0.35-1) | 15.6 (70) |
Nonintensive treatment included no treatment or only erythropoiesis-stimulating agents, blood transfusions, or significantly dose-reduced chemotherapy.
Aggressive malignancies included AML, multiple myeloma (MM), acute lymphoblastic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma (DLBCL).
Indolent malignancies included MDS, chronic lymphocytic leukemia (CLL), myeloproliferative neoplasms (MPNs), marginal zone lymphoma (MZL), follicular lymphoma, hairy cell leukemia, monoclonal gammopathy of unknown significance, smoldering myeloma, and Waldenstrom hypergammaglobulinemia.
Myeloid neoplasms included MPN, MDS, and AML.
Plasma cell neoplasms included MM and Waldenstrom hypergammaglobulinemia.
NHLs included CLL, NHL, DLBCL, and MZL.
Comorbidities were assigned point values based on severity and then summed using Charlson criteria.